0
Upcoming Allied Market Research
2023
Anthrax Vaccine Market

Anthrax Vaccine Market

by Vaccine Type (Cell-free PA Vaccines, Live Vaccines), by Application (Human Use, Animal Use), by End User (Hospitals, Specialty Centers, Others) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Report Code: A11668
Nov 2023 | Pages: NA
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Anthrax Vaccine Market

Request Now !

Anthrax is a serious illness caused by a spore-forming bacterium called Bacillus anthracis. The disease majorly affects wild game and livestock. However, humans can get infected by anthrax bacteria through direct or indirect contact with animals that carry it. The bacteria causing anthrax enters the human body through a wound in the skin. In addition, inhaling bacterial spores and eating contaminated meat can lead to infection. Signs and symptoms of anthrax include skin sores, fever, and vomiting. For the prevention of anthrax, a three-dose series of anthrax vaccines is used. Common types of anthrax vaccines include cell-free protective agent (PA) vaccines and live anthrax vaccines. 

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the anthrax vaccine market.

Top Impacting Factors

The anthrax vaccine market is expanding rapidly due to increase in prevalence of anthrax. Rise in trend of eating of raw and undercooked meat from infected animals acts as a major driver of the global market.

In addition, surge in manufacturing and industrial processing of contaminated animal materials such as hair wool and hide augments the market growth significantly.

Anthrax is majorly prevalent among wild game and livestock. With increase in animal husbandry across the globe, the number of farms is increasing. Individuals working in farms come in close proximity with animals, and hence are at high risk of developing anthrax. This factor acts as a key driving force of the market

However, anthrax disease has a low rate of voluntary screening and this can act as a major restraint for the growth of the anthrax vaccine market. In addition, lack of awareness about anthrax diagnostic tests in countries such as Africa makes it difficult for companies to reach their customers directly in such countries and regions, thereby hampering the market growth.

Key Market Trends

Hospital pharmacies in the distribution channel segment dominated the market. Hospitals act as a major site for vaccination, which is why the sale of anthrax vaccines is high there. Moreover, anthrax vaccines are part of the standard patient practices in hospitals.

The animal use segment led the anthrax vaccine market, as  a high proportion of anthrax vaccines is used for animals. Up to 20% of anthrax cases in humans lead to death. Hence, this has led to the growth of the animal use segment.

Several Chinese manufacturers are involved in producing anthrax vaccines as per the increasing demands. Hence, setting up manufacturing units in China will help propel the mass production and distribution of these vaccines.

Top players of the anthrax vaccine market are Emergent BioSolutions, Colorado Serum, and Merck, Inc., as they hold patents and key technologies for anthrax vaccine development along with the high-end customer segments.

Key Benefits of the Report

  • This study presents the analytical depiction of the anthrax vaccine industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the anthrax vaccine market share.
  • The current market is quantitatively analyzed to highlight the growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Anthrax Vaccine Report

  • Which are the leading players active in the anthrax vaccine market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the anthrax vaccine market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is the anthrax vaccine?
  • What is the anthrax vaccine market prediction in the future?
  • What are the current trends and predicted trends?

Anthrax Vaccine Market Report Highlights

Aspects Details
By Vaccine Type
  • Cell-free PA Vaccines
  • Live Vaccines
By Application
  • Human Use
  • Animal Use
By End User
  • Hospitals
  • Specialty Centers
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Rest of LAMEA)
Key Market Players Zoetis, Inc., Colorado Serum, PharmAthene, Inc., Bayer AG, Biogenesis Bago S.A., Emergent Bio-Solutions, Altimmune (PharmAthene Inc.), Merial, Inc., Merck & Co., Inc., Porton Biopharma Limited
 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: ANTHRAX VACCINE MARKET, BY VACCINE TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Vaccine Type

    • 4.2. Cell-free PA Vaccines

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Live Vaccines

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: ANTHRAX VACCINE MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Human Use

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Animal Use

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: ANTHRAX VACCINE MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Specialty Centers

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: ANTHRAX VACCINE MARKET, BY DISTRIBUTION CHANNEL

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Distribution Channel

    • 7.2. Hospital Pharmacy

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Retail Pharmacy

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Others

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

  • CHAPTER 8: ANTHRAX VACCINE MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Vaccine Type

      • 8.2.3. Market Size and Forecast, By Application

      • 8.2.4. Market Size and Forecast, By End User

      • 8.2.5. Market Size and Forecast, By Distribution Channel

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Anthrax Vaccine Market

        • 8.2.7.1. Market Size and Forecast, By Vaccine Type
        • 8.2.7.2. Market Size and Forecast, By Application
        • 8.2.7.3. Market Size and Forecast, By End User
        • 8.2.7.4. Market Size and Forecast, By Distribution Channel
      • 8.2.8. Canada Anthrax Vaccine Market

        • 8.2.8.1. Market Size and Forecast, By Vaccine Type
        • 8.2.8.2. Market Size and Forecast, By Application
        • 8.2.8.3. Market Size and Forecast, By End User
        • 8.2.8.4. Market Size and Forecast, By Distribution Channel
      • 8.2.9. Mexico Anthrax Vaccine Market

        • 8.2.9.1. Market Size and Forecast, By Vaccine Type
        • 8.2.9.2. Market Size and Forecast, By Application
        • 8.2.9.3. Market Size and Forecast, By End User
        • 8.2.9.4. Market Size and Forecast, By Distribution Channel
    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Vaccine Type

      • 8.3.3. Market Size and Forecast, By Application

      • 8.3.4. Market Size and Forecast, By End User

      • 8.3.5. Market Size and Forecast, By Distribution Channel

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Anthrax Vaccine Market

        • 8.3.7.1. Market Size and Forecast, By Vaccine Type
        • 8.3.7.2. Market Size and Forecast, By Application
        • 8.3.7.3. Market Size and Forecast, By End User
        • 8.3.7.4. Market Size and Forecast, By Distribution Channel
      • 8.3.8. Germany Anthrax Vaccine Market

        • 8.3.8.1. Market Size and Forecast, By Vaccine Type
        • 8.3.8.2. Market Size and Forecast, By Application
        • 8.3.8.3. Market Size and Forecast, By End User
        • 8.3.8.4. Market Size and Forecast, By Distribution Channel
      • 8.3.9. Italy Anthrax Vaccine Market

        • 8.3.9.1. Market Size and Forecast, By Vaccine Type
        • 8.3.9.2. Market Size and Forecast, By Application
        • 8.3.9.3. Market Size and Forecast, By End User
        • 8.3.9.4. Market Size and Forecast, By Distribution Channel
      • 8.3.10. Spain Anthrax Vaccine Market

        • 8.3.10.1. Market Size and Forecast, By Vaccine Type
        • 8.3.10.2. Market Size and Forecast, By Application
        • 8.3.10.3. Market Size and Forecast, By End User
        • 8.3.10.4. Market Size and Forecast, By Distribution Channel
      • 8.3.11. UK Anthrax Vaccine Market

        • 8.3.11.1. Market Size and Forecast, By Vaccine Type
        • 8.3.11.2. Market Size and Forecast, By Application
        • 8.3.11.3. Market Size and Forecast, By End User
        • 8.3.11.4. Market Size and Forecast, By Distribution Channel
      • 8.3.12. Russia Anthrax Vaccine Market

        • 8.3.12.1. Market Size and Forecast, By Vaccine Type
        • 8.3.12.2. Market Size and Forecast, By Application
        • 8.3.12.3. Market Size and Forecast, By End User
        • 8.3.12.4. Market Size and Forecast, By Distribution Channel
      • 8.3.13. Rest Of Europe Anthrax Vaccine Market

        • 8.3.13.1. Market Size and Forecast, By Vaccine Type
        • 8.3.13.2. Market Size and Forecast, By Application
        • 8.3.13.3. Market Size and Forecast, By End User
        • 8.3.13.4. Market Size and Forecast, By Distribution Channel
    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Vaccine Type

      • 8.4.3. Market Size and Forecast, By Application

      • 8.4.4. Market Size and Forecast, By End User

      • 8.4.5. Market Size and Forecast, By Distribution Channel

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Anthrax Vaccine Market

        • 8.4.7.1. Market Size and Forecast, By Vaccine Type
        • 8.4.7.2. Market Size and Forecast, By Application
        • 8.4.7.3. Market Size and Forecast, By End User
        • 8.4.7.4. Market Size and Forecast, By Distribution Channel
      • 8.4.8. Japan Anthrax Vaccine Market

        • 8.4.8.1. Market Size and Forecast, By Vaccine Type
        • 8.4.8.2. Market Size and Forecast, By Application
        • 8.4.8.3. Market Size and Forecast, By End User
        • 8.4.8.4. Market Size and Forecast, By Distribution Channel
      • 8.4.9. India Anthrax Vaccine Market

        • 8.4.9.1. Market Size and Forecast, By Vaccine Type
        • 8.4.9.2. Market Size and Forecast, By Application
        • 8.4.9.3. Market Size and Forecast, By End User
        • 8.4.9.4. Market Size and Forecast, By Distribution Channel
      • 8.4.10. South Korea Anthrax Vaccine Market

        • 8.4.10.1. Market Size and Forecast, By Vaccine Type
        • 8.4.10.2. Market Size and Forecast, By Application
        • 8.4.10.3. Market Size and Forecast, By End User
        • 8.4.10.4. Market Size and Forecast, By Distribution Channel
      • 8.4.11. Australia Anthrax Vaccine Market

        • 8.4.11.1. Market Size and Forecast, By Vaccine Type
        • 8.4.11.2. Market Size and Forecast, By Application
        • 8.4.11.3. Market Size and Forecast, By End User
        • 8.4.11.4. Market Size and Forecast, By Distribution Channel
      • 8.4.12. Thailand Anthrax Vaccine Market

        • 8.4.12.1. Market Size and Forecast, By Vaccine Type
        • 8.4.12.2. Market Size and Forecast, By Application
        • 8.4.12.3. Market Size and Forecast, By End User
        • 8.4.12.4. Market Size and Forecast, By Distribution Channel
      • 8.4.13. Malaysia Anthrax Vaccine Market

        • 8.4.13.1. Market Size and Forecast, By Vaccine Type
        • 8.4.13.2. Market Size and Forecast, By Application
        • 8.4.13.3. Market Size and Forecast, By End User
        • 8.4.13.4. Market Size and Forecast, By Distribution Channel
      • 8.4.14. Indonesia Anthrax Vaccine Market

        • 8.4.14.1. Market Size and Forecast, By Vaccine Type
        • 8.4.14.2. Market Size and Forecast, By Application
        • 8.4.14.3. Market Size and Forecast, By End User
        • 8.4.14.4. Market Size and Forecast, By Distribution Channel
      • 8.4.15. Rest of Asia Pacific Anthrax Vaccine Market

        • 8.4.15.1. Market Size and Forecast, By Vaccine Type
        • 8.4.15.2. Market Size and Forecast, By Application
        • 8.4.15.3. Market Size and Forecast, By End User
        • 8.4.15.4. Market Size and Forecast, By Distribution Channel
    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Vaccine Type

      • 8.5.3. Market Size and Forecast, By Application

      • 8.5.4. Market Size and Forecast, By End User

      • 8.5.5. Market Size and Forecast, By Distribution Channel

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Anthrax Vaccine Market

        • 8.5.7.1. Market Size and Forecast, By Vaccine Type
        • 8.5.7.2. Market Size and Forecast, By Application
        • 8.5.7.3. Market Size and Forecast, By End User
        • 8.5.7.4. Market Size and Forecast, By Distribution Channel
      • 8.5.8. South Africa Anthrax Vaccine Market

        • 8.5.8.1. Market Size and Forecast, By Vaccine Type
        • 8.5.8.2. Market Size and Forecast, By Application
        • 8.5.8.3. Market Size and Forecast, By End User
        • 8.5.8.4. Market Size and Forecast, By Distribution Channel
      • 8.5.9. Saudi Arabia Anthrax Vaccine Market

        • 8.5.9.1. Market Size and Forecast, By Vaccine Type
        • 8.5.9.2. Market Size and Forecast, By Application
        • 8.5.9.3. Market Size and Forecast, By End User
        • 8.5.9.4. Market Size and Forecast, By Distribution Channel
      • 8.5.10. UAE Anthrax Vaccine Market

        • 8.5.10.1. Market Size and Forecast, By Vaccine Type
        • 8.5.10.2. Market Size and Forecast, By Application
        • 8.5.10.3. Market Size and Forecast, By End User
        • 8.5.10.4. Market Size and Forecast, By Distribution Channel
      • 8.5.11. Argentina Anthrax Vaccine Market

        • 8.5.11.1. Market Size and Forecast, By Vaccine Type
        • 8.5.11.2. Market Size and Forecast, By Application
        • 8.5.11.3. Market Size and Forecast, By End User
        • 8.5.11.4. Market Size and Forecast, By Distribution Channel
      • 8.5.12. Rest of LAMEA Anthrax Vaccine Market

        • 8.5.12.1. Market Size and Forecast, By Vaccine Type
        • 8.5.12.2. Market Size and Forecast, By Application
        • 8.5.12.3. Market Size and Forecast, By End User
        • 8.5.12.4. Market Size and Forecast, By Distribution Channel
  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Merck And Co., Inc.

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Emergent Bio-Solutions

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Zoetis, Inc.

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. PharmAthene, Inc.

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Biogenesis Bago S.A.

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Porton Biopharma Limited

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Colorado Serum

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Merial, Inc.

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Altimmune (PharmAthene Inc.)

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Bayer AG

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ANTHRAX VACCINE MARKET, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL ANTHRAX VACCINE MARKET FOR CELL-FREE PA VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL ANTHRAX VACCINE MARKET FOR LIVE VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL ANTHRAX VACCINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL ANTHRAX VACCINE MARKET FOR HUMAN USE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL ANTHRAX VACCINE MARKET FOR ANIMAL USE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL ANTHRAX VACCINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL ANTHRAX VACCINE MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL ANTHRAX VACCINE MARKET FOR SPECIALTY CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL ANTHRAX VACCINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL ANTHRAX VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL ANTHRAX VACCINE MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL ANTHRAX VACCINE MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL ANTHRAX VACCINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL ANTHRAX VACCINE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA ANTHRAX VACCINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. U.S. ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 22. U.S. ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. U.S. ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. U.S. ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. CANADA ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 26. CANADA ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. CANADA ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. CANADA ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE ANTHRAX VACCINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. FRANCE ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. GERMANY ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 43. GERMANY ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. GERMANY ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. GERMANY ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. ITALY ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 47. ITALY ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. ITALY ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. ITALY ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. SPAIN ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 51. SPAIN ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 52. SPAIN ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. SPAIN ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. UK ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 55. UK ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 56. UK ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. UK ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. RUSSIA ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 59. RUSSIA ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 60. RUSSIA ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. RUSSIA ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. REST OF EUROPE ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 63. REST OF EUROPE ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. REST OF EUROPE ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. REST OF EUROPE ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. ASIA-PACIFIC ANTHRAX VACCINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 67. ASIA-PACIFIC ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 68. ASIA-PACIFIC ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 69. ASIA-PACIFIC ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. CHINA ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 72. CHINA ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. CHINA ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. CHINA ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. JAPAN ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 76. JAPAN ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 77. JAPAN ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 78. JAPAN ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. INDIA ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 80. INDIA ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 81. INDIA ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 82. INDIA ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH KOREA ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH KOREA ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH KOREA ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH KOREA ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. AUSTRALIA ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 88. AUSTRALIA ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 89. AUSTRALIA ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. AUSTRALIA ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 91. THAILAND ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 92. THAILAND ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 93. THAILAND ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 94. THAILAND ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 95. MALAYSIA ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 96. MALAYSIA ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 97. MALAYSIA ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 98. MALAYSIA ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. INDONESIA ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 100. INDONESIA ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 101. INDONESIA ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 102. INDONESIA ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 103. REST OF ASIA PACIFIC ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 104. REST OF ASIA PACIFIC ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 105. REST OF ASIA PACIFIC ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 106. REST OF ASIA PACIFIC ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 107. LAMEA ANTHRAX VACCINE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 108. LAMEA ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 109. LAMEA ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 110. LAMEA ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 111. LAMEA ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 112. BRAZIL ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 113. BRAZIL ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 114. BRAZIL ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 115. BRAZIL ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 116. SOUTH AFRICA ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 117. SOUTH AFRICA ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 118. SOUTH AFRICA ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 119. SOUTH AFRICA ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 120. SAUDI ARABIA ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 121. SAUDI ARABIA ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 122. SAUDI ARABIA ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 123. SAUDI ARABIA ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 124. UAE ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 125. UAE ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 126. UAE ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 127. UAE ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 128. ARGENTINA ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 129. ARGENTINA ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 130. ARGENTINA ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 131. ARGENTINA ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 132. REST OF LAMEA ANTHRAX VACCINE, BY VACCINE TYPE, 2022-2032 ($MILLION)
  • TABLE 133. REST OF LAMEA ANTHRAX VACCINE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 134. REST OF LAMEA ANTHRAX VACCINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 135. REST OF LAMEA ANTHRAX VACCINE, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 136. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 137. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 138. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 139. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 140. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. EMERGENT BIO-SOLUTIONS: KEY EXECUTIVES
  • TABLE 142. EMERGENT BIO-SOLUTIONS: COMPANY SNAPSHOT
  • TABLE 143. EMERGENT BIO-SOLUTIONS: OPERATING SEGMENTS
  • TABLE 144. EMERGENT BIO-SOLUTIONS: PRODUCT PORTFOLIO
  • TABLE 145. EMERGENT BIO-SOLUTIONS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. ZOETIS, INC.: KEY EXECUTIVES
  • TABLE 147. ZOETIS, INC.: COMPANY SNAPSHOT
  • TABLE 148. ZOETIS, INC.: OPERATING SEGMENTS
  • TABLE 149. ZOETIS, INC.: PRODUCT PORTFOLIO
  • TABLE 150. ZOETIS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. PHARMATHENE, INC.: KEY EXECUTIVES
  • TABLE 152. PHARMATHENE, INC.: COMPANY SNAPSHOT
  • TABLE 153. PHARMATHENE, INC.: OPERATING SEGMENTS
  • TABLE 154. PHARMATHENE, INC.: PRODUCT PORTFOLIO
  • TABLE 155. PHARMATHENE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 156. BIOGENESIS BAGO S.A.: KEY EXECUTIVES
  • TABLE 157. BIOGENESIS BAGO S.A.: COMPANY SNAPSHOT
  • TABLE 158. BIOGENESIS BAGO S.A.: OPERATING SEGMENTS
  • TABLE 159. BIOGENESIS BAGO S.A.: PRODUCT PORTFOLIO
  • TABLE 160. BIOGENESIS BAGO S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 161. PORTON BIOPHARMA LIMITED: KEY EXECUTIVES
  • TABLE 162. PORTON BIOPHARMA LIMITED: COMPANY SNAPSHOT
  • TABLE 163. PORTON BIOPHARMA LIMITED: OPERATING SEGMENTS
  • TABLE 164. PORTON BIOPHARMA LIMITED: PRODUCT PORTFOLIO
  • TABLE 165. PORTON BIOPHARMA LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 166. COLORADO SERUM: KEY EXECUTIVES
  • TABLE 167. COLORADO SERUM: COMPANY SNAPSHOT
  • TABLE 168. COLORADO SERUM: OPERATING SEGMENTS
  • TABLE 169. COLORADO SERUM: PRODUCT PORTFOLIO
  • TABLE 170. COLORADO SERUM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 171. MERIAL, INC.: KEY EXECUTIVES
  • TABLE 172. MERIAL, INC.: COMPANY SNAPSHOT
  • TABLE 173. MERIAL, INC.: OPERATING SEGMENTS
  • TABLE 174. MERIAL, INC.: PRODUCT PORTFOLIO
  • TABLE 175. MERIAL, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 176. ALTIMMUNE (PHARMATHENE INC.): KEY EXECUTIVES
  • TABLE 177. ALTIMMUNE (PHARMATHENE INC.): COMPANY SNAPSHOT
  • TABLE 178. ALTIMMUNE (PHARMATHENE INC.): OPERATING SEGMENTS
  • TABLE 179. ALTIMMUNE (PHARMATHENE INC.): PRODUCT PORTFOLIO
  • TABLE 180. ALTIMMUNE (PHARMATHENE INC.): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 181. BAYER AG: KEY EXECUTIVES
  • TABLE 182. BAYER AG: COMPANY SNAPSHOT
  • TABLE 183. BAYER AG: OPERATING SEGMENTS
  • TABLE 184. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 185. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTHRAX VACCINE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ANTHRAX VACCINE MARKET
  • FIGURE 3. SEGMENTATION ANTHRAX VACCINE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ANTHRAX VACCINE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALANTHRAX VACCINE MARKET
  • FIGURE 11. ANTHRAX VACCINE MARKET SEGMENTATION, BY BY VACCINE TYPE
  • FIGURE 12. ANTHRAX VACCINE MARKET FOR CELL-FREE PA VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. ANTHRAX VACCINE MARKET FOR LIVE VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. ANTHRAX VACCINE MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. ANTHRAX VACCINE MARKET FOR HUMAN USE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. ANTHRAX VACCINE MARKET FOR ANIMAL USE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. ANTHRAX VACCINE MARKET SEGMENTATION, BY BY END USER
  • FIGURE 18. ANTHRAX VACCINE MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. ANTHRAX VACCINE MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. ANTHRAX VACCINE MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. ANTHRAX VACCINE MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 22. ANTHRAX VACCINE MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. ANTHRAX VACCINE MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. ANTHRAX VACCINE MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: ANTHRAX VACCINE MARKET
  • FIGURE 31. Top player positioning, 2022
  • FIGURE 32. MERCK AND CO., INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. EMERGENT BIO-SOLUTIONS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. EMERGENT BIO-SOLUTIONS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. EMERGENT BIO-SOLUTIONS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. ZOETIS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. ZOETIS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. ZOETIS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. PHARMATHENE, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. PHARMATHENE, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. PHARMATHENE, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. BIOGENESIS BAGO S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. BIOGENESIS BAGO S.A.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. BIOGENESIS BAGO S.A.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. PORTON BIOPHARMA LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. PORTON BIOPHARMA LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. PORTON BIOPHARMA LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. COLORADO SERUM: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. COLORADO SERUM: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. COLORADO SERUM: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. MERIAL, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. MERIAL, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. MERIAL, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. ALTIMMUNE (PHARMATHENE INC.): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. ALTIMMUNE (PHARMATHENE INC.): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. ALTIMMUNE (PHARMATHENE INC.): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 59. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. BAYER AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 61. BAYER AG: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Anthrax Vaccine Market

Start reading.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers